2016 Deadline: September 20, 2016 for consideration at the December 2016 Board of Directors Meeting.
Submission date subject to change. Please refer to PRF website for updates.
The Progeria Research Foundation (PRF) is the only organization in the world dedicated to discovering treatments and the cure for Progeria and its aging-related disorders. Progeria is a rare, fatal, “premature aging” disease that affects children, who die of heart disease (heart attacks or stroke) at an average age of 14 years - the same heart disease that affects millions of normal aging adults (atherosclerosis). Scientific studies have solidified biological links between Progeria, heart disease and aging. Investigation of the disease mechanism Progeria will help not only children with Progeria, but has implications for heart attacks, strokes and other aging-related conditions.
PRF encourages proposals in the areas listed below. Investigators are not limited to applications that address these priorities, but rather are encouraged to use them to better understand the needs of the field at this time.
PRF is seeking proposals that address the following priorities:
1. Discovery of biological markers of disease in HGPS that can be assessed in human and/or mouse samples. Highest priority will be given to those markers that can be assayed in easily obtainable human samples such as blood, urine, and cheek swabs. In addition, proposals that explore biomarker relevance to disease process and /or change in markers with disease treatment are encouraged.
2. Discovery and/or testing of candidate treatment compounds in both cell based and mouse models of HGPS. Of note, proposals should test compounds in a progerin-producing mouse model as the priority. Comparisons to other mouse models of disease, such as ZMPSTE24 -/- and other non-progerin producing mouse models is acceptable, but only as a comparison to progerin-producing models.
Visit the PRFWeb site for complete program information: www.progeriaresearch.org
Awards are given in 3 categories with varying funding levels and length of time of up to $100,000 per year, for up to three years. Projects must have specific relevance to HGPS, and show promise for contributing to the scientific or clinical advancement in this field of study.
Principal investigators must hold post-doctoral positions or beyond. PI’s wishing to have a project performed by a post-doctoral associate must act as co-principal investigators.
Awards will be granted only to applicants affiliated with institutions with 501(c)3 status, or the equivalent for foreign institutions.
RFP Link: www.progeriaresearch.org/grant_application.html
or contact The Progeria Research Foundation at 978-535-2594 or firstname.lastname@example.org